BioCentury | Jan 20, 2017
Clinical News

PXT864: PLEODIAL-II extension study data

...GABA B receptor Description: Fixed-dose combination of baclofen , a GABA B receptor agonist, and acamprosate...
BioCentury | Jan 12, 2015
Clinical News

Pharnext preclinical data

...with neuroinflammation. Data were published in Scientific Reports. PXT-864, a low-dose combination of baclofen and acamprosate...
BioCentury | Jul 3, 2014
Financial News

Synchroneuron secures $20 million in series B

...led by existing investor Morningside Technology Ventures. The company's SNC-102 , a sustained-release formulation of acamprosate...
BioCentury | Mar 3, 2014
Clinical News

Acamprosate: Phase II started

...Synchroneuron began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate oral SNC-102 once or twice...
...Mass. Product: Acamprosate ( SNC-102 ) Business: Neurology Molecular target: NA Description: Sustained-release formulation of acamprosate...
BioCentury | Jun 25, 2012
Strategy

Fragile X connection

...to compete for patients with "a lot of smaller academic trials ongoing with donepezil, memantine, acamprosate...
BioCentury | Mar 25, 2010
Targets & Mechanisms

SK channel activation for alcoholism

...at the Ernest Gallo Center, told SciBX that "existing pharmacotherapies for alcoholism, including naltrexone and acamprosate...
...formulation of naltrexone, to treat alcohol dependence. Forest Laboratories Inc. and Merck KGaA market Campral acamprosate...
BioCentury | Apr 25, 2005
Clinical News

Acamprosate calcium neurology data

...Darmstadt, Germany Product: Acamprosate calcium ( Campral - EU) Business: Neurology Molecular target: Unknown Description: Acamprosate...
BioCentury | Apr 25, 2005
Clinical News

Acamprosate calcium: Post-marketing study data

...Merck KGaA (FSE:MRK), Darmstadt, Germany Business: Neurology Product: Acamprosate calcium ( Campral - EU) Description: Acamprosate...
BioCentury | Apr 18, 2005
Strategy

Reprofiler report card

...new formulation of acamprosate to treat movement disorders. The use patents for both doxepin and acamprosate...
...pathological gambling this year, with the goal of submitting an NDA in 2008, Cohen said. Acamprosate...
...butyric acid (GABA) and glutamate. Although the exact mechanism is not clear, research suggests that acamprosate...
BioCentury | Jan 17, 2005
Company News

Forest Laboratories sales and marketing update

...FRX launched its Campral acamprosate delayed-released tablets to treat alcohol dependence in patients who are abstinent...
Items per page:
1 - 10 of 20